[go: up one dir, main page]

MX2019013570A - Particulas portadoras novedosas para formulaciones de polvo seco para inhalacion. - Google Patents

Particulas portadoras novedosas para formulaciones de polvo seco para inhalacion.

Info

Publication number
MX2019013570A
MX2019013570A MX2019013570A MX2019013570A MX2019013570A MX 2019013570 A MX2019013570 A MX 2019013570A MX 2019013570 A MX2019013570 A MX 2019013570A MX 2019013570 A MX2019013570 A MX 2019013570A MX 2019013570 A MX2019013570 A MX 2019013570A
Authority
MX
Mexico
Prior art keywords
inhalation
dry powder
carrier particles
powder formulations
novel carrier
Prior art date
Application number
MX2019013570A
Other languages
English (en)
Other versions
MX388235B (es
Inventor
Schiaretti Francesca
Buttini Francesca
Bettini Ruggero
Salomi Enrico
Benassi Andrea
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MX2019013570A publication Critical patent/MX2019013570A/es
Publication of MX388235B publication Critical patent/MX388235B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención tiene que ver con partículas portadoras en forma de gránulos que son adecuadas para el uso en formulaciones de polvo seco para la inhalación, y que comprenden preferiblemente ingredientes activos en dosis de alta resistencia. La invención también se refiere a procesos para su preparación.
MX2019013570A 2017-05-17 2018-05-16 Partículas portadoras novedosas para formulaciones de polvo seco para inhalación. MX388235B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17171586 2017-05-17
PCT/EP2018/062671 WO2018210909A1 (en) 2017-05-17 2018-05-16 Novel carrier particles for dry powder formulations for inhalation

Publications (2)

Publication Number Publication Date
MX2019013570A true MX2019013570A (es) 2019-12-18
MX388235B MX388235B (es) 2025-03-19

Family

ID=58715070

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013570A MX388235B (es) 2017-05-17 2018-05-16 Partículas portadoras novedosas para formulaciones de polvo seco para inhalación.

Country Status (9)

Country Link
US (2) US10583085B2 (es)
EP (1) EP3624768A1 (es)
KR (1) KR102746519B1 (es)
CN (1) CN110621299A (es)
CA (1) CA3060022A1 (es)
MA (1) MA49130A (es)
MX (1) MX388235B (es)
RU (1) RU2745045C1 (es)
WO (1) WO2018210909A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112870337A (zh) * 2021-01-26 2021-06-01 浙江科瑞特生物科技有限公司 一种血促性素和绒促性素复合激素冻干粉及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9404945D0 (en) * 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
US5622166A (en) * 1995-04-24 1997-04-22 Dura Pharmaceuticals, Inc. Dry powder inhaler delivery system
AU3409399A (en) * 1999-03-05 2000-09-28 Chiesi Farmaceutici S.P.A. Improved powdery pharmaceutical compositions for inhalation
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
AU2002308143A1 (en) * 2002-04-12 2003-10-27 Campina Nederland Holding B.V. Excipient for use in dry powder inhalation preparations
PT1386630E (pt) 2002-07-31 2006-09-29 Chiesi Farma Spa Inalador em po
JP5154078B2 (ja) 2003-02-21 2013-02-27 ザ ユニヴァーシティ オブ バース 粒子の製造プロセス
JO3102B1 (ar) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
ES2344119T3 (es) * 2004-12-22 2010-08-18 Campina Nederland Holding B.V. Aglomerados de lactosa anhidro y su preparacion.
GB0705159D0 (en) 2007-03-19 2007-04-25 Prosonix Ltd Process for making crystals
GB0711680D0 (en) 2007-06-18 2007-07-25 Prosonix Ltd Process
AU2009272445B2 (en) 2008-07-18 2012-11-22 Circassia Limited Process for improving crystallinity
SG184352A1 (en) * 2010-04-01 2012-10-30 Chiesi Farma Spa Process for preparing carrier particles for dry powders for inhalation
KR101863523B1 (ko) * 2010-04-21 2018-05-31 키에시 파르마슈티시 엣스. 피. 에이. 정전하가 감소된 입자를 제공하는 방법
EA024922B1 (ru) * 2010-08-03 2016-11-30 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Сухой порошковый препарат, содержащий ингибитор фосфодиэстеразы

Also Published As

Publication number Publication date
US20200163883A1 (en) 2020-05-28
RU2745045C1 (ru) 2021-03-18
CN110621299A (zh) 2019-12-27
US10583085B2 (en) 2020-03-10
US20180333359A1 (en) 2018-11-22
US10709666B2 (en) 2020-07-14
BR112019024132A2 (pt) 2020-06-02
CA3060022A1 (en) 2018-11-22
EP3624768A1 (en) 2020-03-25
MA49130A (fr) 2021-04-28
MX388235B (es) 2025-03-19
KR102746519B1 (ko) 2024-12-26
KR20200004816A (ko) 2020-01-14
WO2018210909A1 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
BR112017011215A2 (pt) partículas de distribuição de pró-flavorizante
CL2015002860A1 (es) Antagonistas de la alfa-v-beta-6 integrina
BR112017008499A2 (pt) métodos e composições relacionadas com o uso de tensoativos de baixo valor de hlb na produção de nanoportadores sintéticos compreendendo um rapalog
BR112015014482A2 (pt) vacinas para vírus influenza e seus usos
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
BR112015023629A2 (pt) formulação de acetato de abiraterona
SV2016005236A (es) Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina
BR112017005137A2 (pt) sistemas e métodos para secagem de pellets e outros materiais
MX2018005384A (es) Composiciones y metodos para fabricar microparticulas de proteina.
PE20151759A1 (es) Imidazopiridazinas sustituidas
MX378141B (es) Composición farmacéutica, que comprende partículas de aglutinante de fosfato.
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
CO2017004504A2 (es) Composición que comprende al menos un polvo seco obtenido por secado por atomización para aumentar la estabilidad de la formulación
BR112015029773A2 (pt) pós revestidos com aroma
MX2016017142A (es) Dispersion solida de allisartan isoproxilo y composicion farmaceutica que comprende la misma.
BR112016013577A2 (pt) Proteínas de fusão, seu uso e composição farmacêutica
TR201902687T4 (tr) İri parçacıklı kristal malzemelerin koşullandırılması için yöntemler ve sistemler.
MX2019013570A (es) Particulas portadoras novedosas para formulaciones de polvo seco para inhalacion.
CL2016001359A1 (es) Método para preparar una composición seca para inhalación en polvo que comprende un primer y segundo ingrediente activo en forma micronizada.
MX2018001265A (es) Particulas de limpieza y su uso.
BR112017014083A2 (pt) artigos abrasivos e métodos para formar os mesmos
DOP2018000247A (es) Procedimiento para la preparación de cuerpos moldeados para la administración a animales
BR112015024877A2 (pt) vacinas que compreendem polipeptídeos de leishmania para o tratamento e diagnóstico de leishmaniose
IT201600122377A1 (it) Composti di coordinazione e loro formulati, metodi di preparazione ed uso degli stessi come agenti ad azione antiflogistica
CL2018002542A1 (es) Na2-imp deshidratada como agente antiaglomerante